Q4 2025 Azenta Inc Earnings Call Transcript
Key Points
- Azenta Inc (AZTA) achieved 3% core growth and delivered meaningful margin expansion of 310 basis points in fiscal 2025.
- The company has a strong balance sheet with over $0.5 billion in cash, cash equivalents, and marketable securities, providing financial flexibility.
- Azenta Inc (AZTA) implemented the Azenta Business System (ABS), leading to measurable improvements in quality, on-time delivery, and overall productivity.
- The Multi-Omics segment delivered a record quarter with 11% growth on a reported basis and 10% organic growth.
- Azenta Inc (AZTA) is well-positioned to capitalize on outsourcing trends and automation, areas where the company is a leader.
- The macroeconomic environment remains challenging, with softer academic and NIH funding and ongoing geopolitical uncertainty impacting growth.
- Azenta Inc (AZTA) experienced a decline in Sanger sequencing revenue, which fell by low double digits year-over-year.
- The company anticipates a slower start in fiscal 2026, with first-quarter revenue expected to decline approximately 1% to 2% year-over-year.
- Capital expenditures in stores and cryogenic solutions are impacted by ongoing customer budget constraints and macroeconomic uncertainty.
- The government shutdown caused delays in new grant reviews and approvals, affecting bookings and pushing some revenue into future quarters.
Greetings, and welcome to the Azenta Q4 2025 financial results. (Operator Instructions) As a reminder, this conference is being recorded Friday, November 21, 2025. I will now turn the conference over to Yvonne Perron, Vice President, FP&A and Investor Relations.
Thank you, operator, and good morning to everyone on the line today. We would like to welcome you to our earnings conference call for the fourth quarter of fiscal year 2025. Our fourth quarter earnings press release was issued before the open of the market today and is available on our Investor Relations web located at investors.azenta.com in addition to the supplementary PowerPoint slides that will be used during the prepared remarks today.
Please note that effective the first fiscal quarter of 2025, the results of B Medical Systems are treated as discontinued operations. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
